Overview

Study to Evaluate Safety and Antitumor Activity of Lete-Cel (GSK3377794) in HLA-A2+ Participants With NY-ESO-1 Positive Previously Untreated Advanced (Metastatic or Unresectable) Synovial Sarcoma and Myxoid/Round Cell Liposarcoma

Status:
Active, not recruiting

Trial end date:
2024-07-01

Target enrollment:

Participant gender:

Summary

This trial will evaluate safety and efficacy of human engineered T-cell therapies, in participants with advanced tumors. This trial is a sub study of the Master study NCT03967223.

Phase:

Phase 2

Details

Lead Sponsor:

GlaxoSmithKline

Treatments:

Cyclophosphamide
Fludarabine